About Us

Our Strengths

Our key strengths include the following:

• Sales growth of RUCONEST®.

• Proven rare-disease commercialization capabilities.

• Internal pipeline of product candidates.

• Transgenic Production Platform Technology.

• Data exclusivity, know-how and intellectual property.

Our Strategy

Our goal is to be a leading biopharmaceutical company focused on offering treatment options for patients with unmet medical needs, focused on rare diseases.

Our three-pillar strategy for achieving our goal is:

• Continuing to grow sales of RUCONEST® through further country launches and increasing acute HAE attack treatment market share

• Expanding indications for rhC1INH and clinical development and commercialization of new recombinant human proteins using our platform technology

  • rhC1INH for additional large unmet indications, such as Acute Kidney Injury, Pre-eclampsia, and COVID-19.

  • Developing more convenient forms of RUCONEST®.

  • Leveraging our transgenic manufacturing technology to develop next-generation protein replacement therapies.

• In-licensing or acquiring drug candidates that are in the late-stages of clinical development and that can potentially leverage our commercial infrastructure

  • Developing leniolisib for the treatment of APDS.

  • Developing or acquiring new programs or companies that can be commercialized using our sales and marketing infrastructure.